| Ident. | Authors (with country if any) | Title |
|---|
| 000356 |
Jonathan E. Golub [États-Unis] ; Paul Pronyk [Royaume-Uni, Afrique du Sud] ; Lerato Mohapi [Afrique du Sud] ; Nkeko Thsabangu [Afrique du Sud] ; Mosa Moshabela [Afrique du Sud] ; Helen Struthers [Afrique du Sud] ; Glenda E. Gray [Afrique du Sud] ; James A. Mclntyre [Afrique du Sud] ; Richard E. Chaisson [États-Unis] ; Neil A. Martinson [États-Unis, Afrique du Sud] | Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa : a prospective cohort |
| 000742 |
Alwyn Mwinga [Zambie] ; Maria Hosp [Zambie] ; Isaac Zulu [Zambie, Royaume-Uni] ; Michael J. G. Farthing [Royaume-Uni] ; Sylvia Mulambo [Zambie] ; Paul Kelly [Zambie, Royaume-Uni] | Tuberculosis preventative treatment also prevented diarrhoea in HIV-infected patients in Zambia |
| 000761 |
John E. Jellis [Zambie] | Human immunodeficiency virus and osteoarticular tuberculosis : Osteoarticular Tuberculosis |
| 000797 |
Maria A. Quigley [Royaume-Uni] ; Alwyn Mwinga [Zambie] ; Maria Hosp [Zambie] ; Ida Lisse [Danemark, Guinée-Bissau] ; Dietmar Fuchs [Autriche] ; John D. H. Porter [Royaume-Uni] ; Peter Godfrey-Faussett [Royaume-Uni] | Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults |
| 000842 |
A. D. Harries [Malawi] ; N. J. Hargreaves [Malawi, Royaume-Uni] ; J. Kumwenda [Malawi] ; J. H. Kwanjana [Malawi] ; F. M. Salaniponi [Malawi] | Trials of anti-tuberculosis treatment in areas of high human immunodeficiency virus prevalence in sub-Saharan Africa |
| 000879 |
J. C. Bell [États-Unis] ; D. N. Rose [États-Unis] ; H. S. Sacks [États-Unis] | Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective |
| 000881 |
S. D. Lawn [États-Unis, Royaume-Uni] ; R. J. Shattock [Royaume-Uni] ; J. W. Acheampong [Ghana] ; R. B. Lal [États-Unis] ; T. M. Folks [États-Unis] ; G. E. Griffin [Royaume-Uni] ; S. T. Butera [États-Unis] | Sustained plasma TNF-α and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans |
| 000883 |
P. Godfrey-Faussett [Royaume-Uni] ; M. Quigley [Royaume-Uni] ; H. Ayles [Royaume-Uni, Zambie] ; AIWYN MWINGA [Zambie] ; M. Hosp [Royaume-Uni] ; J. Porter [Royaume-Uni] | Screening people living with HIV before tuberculosis preventative therapy |
| 000887 |
H. C. Bucher [Suisse] ; L. E. Griffith [Canada] ; G. H. Guyatt [Canada] ; P. Sudre [Suisse] ; M. Naef [Suisse] ; P. Sendi [Suisse] ; M. Battegay [Suisse] | Isoniazid prophylaxis for tuberculosis in HIV infection : a meta-analysis of randomized controlled trials |
| 000906 |
A. D. Harries [Malawi] | Tuberculosis in HIV-infected persons with special emphasis on Sub-Saharan Africa |
| 000942 |
S. Foster [Royaume-Uni] ; P. Godfrey-Faussett [Zambie, Royaume-Uni] ; J. Porter [Royaume-Uni] | Modelling the economic benefits of tuberculosis preventive therapy for people with HIV : the example of Zambia |
| 000A10 |
P. Kelly [Zambie] ; A. Buve ; S. D. Foster ; M. Mckenna ; M. Donnelly ; G. Sipatunyana | Cutaneous reactions to thiacetazone in Zambia-implications for tuberculosis treatment strategies |
